SV2002000571A - IMIDAZOL DERIVATIVES REF. PC10825 / 20211 / BB - Google Patents
IMIDAZOL DERIVATIVES REF. PC10825 / 20211 / BBInfo
- Publication number
- SV2002000571A SV2002000571A SV2001000571A SV2001000571A SV2002000571A SV 2002000571 A SV2002000571 A SV 2002000571A SV 2001000571 A SV2001000571 A SV 2001000571A SV 2001000571 A SV2001000571 A SV 2001000571A SV 2002000571 A SV2002000571 A SV 2002000571A
- Authority
- SV
- El Salvador
- Prior art keywords
- formula
- compounds
- syndrome
- hair
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
LA INVENCION PROPORCIONA COMPUESTOS DE FORMULA, VER FORMULA, EN LA QUE R1, R2, R3 Y R4 SON COMO SE HA DEFINIDO, Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. SE INDICA QUE LOS COMPUESTOS DE FORMULA 1 TIENEN ACTIVIDAD INHIBIDORA DE CDK5, CDK2 Y GSK-3 TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS QUE COMPRENDEN COMPUESTOS DE FORMULA 1 PARA TRATAR Y PREVENIR ENFERMEDADES Y AFECCIONES QUE COMPRENDEN UN CRECIMIENTO CELULAR ANORMAL, TAL COMO EL CANCER, ENFERMEDADES Y AFECCIONES NEURODEGENERATIVAS, Y LAS AFECTADAS POR LA NEUROTRANSMISION DE DOPAMINA. TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS QUE COMPRENDEN COMPUESTOS DE FORMULA 1 PARA TRATAR LA FERTILIDAD MASCULINA Y MOTILIDAD DE LOS ESPERMATOZOIDES; DIABETES MELLITUS; DISMINUCION DE LA TOLERANCIA DE LA GLUCOSA; SINDROME METABOLICO O SINDROME X; SINDROME DE OVARIOS POLIQUISTICOS; ADIPOGENESIS Y OBESIDAD; MIOGENESIS Y DEBILIDAD, POR EJEMPLO, LA REDUCCION DEL RENDIMIENTO FISICO RELACIONADO CON LA EDAD; SARCOPENIA AGUDA, POR EJEMPLO, ATROFIA MUSCULAR Y/O CAQUEXIA ASOCIADA CON QUEMADURAS, REPOSO EN CAMA, INMOVILIZACION DE MIEMBROS O CIRUGIA TORACICA, ABDOMINAL Y/U ORTOPEDICA MAYOR; SEPSIS; PERDIDA DEL CABELLO, DEBILITAMIENTO DEL CABELLO Y CALVICIE; E INMUNODEFICIENCIA.THE INVENTION PROVIDES FORMULA COMPOUNDS, SEE FORMULA, IN WHICH R1, R2, R3 AND R4 ARE AS DEFINED, AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS. IT IS INDICATED THAT THE FORMULA 1 COMPOUNDS HAVE INHIBITING ACTIVITY OF CDK5, CDK2 AND GSK-3 ALSO DESCRIBE PHARMACEUTICAL COMPOSITIONS AND PROCEDURES THAT UNDERSTAND FORMULA COMPOUNDS TO TREAT AND PREVENT DISEASES AND UNCERTAIN THAN THE CANCER , NEURODEGENERATIVE DISEASES AND AFFECTIONS, AND THOSE AFFECTED BY THE DOPAMINE NEUROTRANSMISSION. PHARMACEUTICAL COMPOSITIONS AND PROCEDURES THAT INCLUDE FORMULA 1 COMPOUNDS ARE ALSO DESCRIBED TO TREAT THE MALE FERTILITY AND MOTILITY OF SpermATOZOIDS; MELLITUS DIABETES; DECREASE OF THE GLUCOSE TOLERANCE; METABOLIC SYNDROME OR X SYNDROME; SYNDROME OF POLYCHISTIC OVARIES; ADIPOGENESIS AND OBESITY; MIOGENESIS AND WEAKNESS, FOR EXAMPLE, THE REDUCTION OF PHYSICAL PERFORMANCE RELATED TO AGE; ACUTE SARCOPENIA, FOR EXAMPLE, MUSCULAR ATROPHY AND / OR CAQUEXY ASSOCIATED WITH BURNS, BED REST, IMMOBILIZATION OF MEMBERS OR TORACICA SURGERY, ABDOMINAL AND / OR MAJOR ORTHOPEDIC; SEPSIS; LOSS OF HAIR, WEAKENING OF HAIR AND CALVICIE; AND IMMUNODEFICIENCY.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22172400P | 2000-07-31 | 2000-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2002000571A true SV2002000571A (en) | 2002-10-24 |
Family
ID=22829075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2001000571A SV2002000571A (en) | 2000-07-31 | 2001-07-27 | IMIDAZOL DERIVATIVES REF. PC10825 / 20211 / BB |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1305295A1 (en) |
| JP (2) | JP4166084B2 (en) |
| KR (1) | KR20030019644A (en) |
| CN (1) | CN1444567A (en) |
| AP (1) | AP2001002232A0 (en) |
| AR (1) | AR032629A1 (en) |
| AU (1) | AU2001270944A1 (en) |
| BG (1) | BG107469A (en) |
| BR (1) | BR0112862A (en) |
| CA (1) | CA2418115A1 (en) |
| CR (1) | CR6861A (en) |
| CZ (1) | CZ2003225A3 (en) |
| DO (1) | DOP2001000220A (en) |
| EA (1) | EA200300097A1 (en) |
| EC (1) | ECSP034445A (en) |
| EE (1) | EE200300049A (en) |
| GT (1) | GT200100147A (en) |
| HR (1) | HRP20030048A2 (en) |
| HU (1) | HUP0303069A3 (en) |
| IL (1) | IL153787A0 (en) |
| IS (1) | IS6662A (en) |
| MA (1) | MA26932A1 (en) |
| MX (1) | MXPA03000939A (en) |
| NO (1) | NO20030472L (en) |
| NZ (1) | NZ523272A (en) |
| OA (1) | OA12345A (en) |
| PA (1) | PA8523701A1 (en) |
| PE (1) | PE20020337A1 (en) |
| PL (1) | PL365134A1 (en) |
| SK (1) | SK1042003A3 (en) |
| SV (1) | SV2002000571A (en) |
| TN (1) | TNSN01114A1 (en) |
| UY (1) | UY26862A1 (en) |
| WO (1) | WO2002010141A1 (en) |
| ZA (1) | ZA200300819B (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1042251B (en) | 1999-01-13 | 2012-07-20 | Bayer Healthcare Llc | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| ME00275B (en) | 1999-01-13 | 2011-02-10 | Bayer Corp | ?-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| WO2003106455A1 (en) | 2002-06-14 | 2003-12-24 | Applied Research Systems Ars Holding N.V. | Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| US7141561B2 (en) | 2002-07-25 | 2006-11-28 | Sanofi-Aventis Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
| DE10233817A1 (en) * | 2002-07-25 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
| GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
| PT1626714E (en) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | DIARILURIES FOR PDGFR MEDICATED DISEASES |
| DE602004010407T2 (en) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING |
| US7342118B2 (en) | 2004-03-23 | 2008-03-11 | Pfizer Inc | Imidazole compounds for the treatment of neurodegenerative disorders |
| ATE517885T1 (en) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES FOR THE TREATMENT OF CANCER |
| RU2399614C2 (en) | 2004-09-21 | 2010-09-20 | Астеллас Фарма Инк. | Amino alcohol derivatives |
| WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| JP2009506069A (en) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | Neurogenesis through modulation of muscarinic receptors |
| RS20080139A (en) * | 2005-09-22 | 2009-05-06 | Pfizer Products Inc., | Imidazole coumpounds for the treatment of neurological disorders |
| JP2009512711A (en) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Regulation of neurogenesis by PDE inhibition |
| JP2009513672A (en) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | GABA receptor-mediated regulation of neurogenesis |
| KR20080091369A (en) | 2006-01-18 | 2008-10-10 | 암젠 인크 | Thiazole Compounds as Protein Kinase Inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| MX2009004140A (en) * | 2006-10-21 | 2009-07-10 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors. |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| MX2010011663A (en) * | 2008-04-24 | 2011-01-21 | Abbott Gmbh & Co Kg | 1- (7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3). |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2012041814A1 (en) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| PT2928474T (en) | 2012-12-07 | 2019-01-30 | Chemocentryx Inc | Diazole lactams |
| DK2935227T3 (en) * | 2012-12-21 | 2017-12-04 | Chemocentryx Inc | DIAZOLAMIDES AS CCR1 RECEPTOR ANTAGONISTS |
| JP6616190B2 (en) * | 2014-02-07 | 2019-12-04 | 国立大学法人 東京医科歯科大学 | Muscle formation promoter, muscle atrophy inhibitor, pharmaceutical composition, and TAZ activator |
| PL3344273T3 (en) | 2015-08-31 | 2020-06-01 | Nutramax Laboratories, Inc. | Compositions comprising magnolia, phellodendron, theanine and/or whey protein |
| GB201605126D0 (en) | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
| CN109310677A (en) | 2016-04-07 | 2019-02-05 | 凯莫森特里克斯股份有限公司 | Reduction of tumor burden by co-administration of CCR1 antagonists with PD-1 inhibitors or PD-L1 antagonists |
| CN111018840B (en) * | 2017-10-25 | 2022-09-09 | 西南大学 | 3-imidazole substituted isatin alcohol compound and preparation method and medical application thereof |
| JP7482122B2 (en) * | 2018-07-03 | 2024-05-13 | アイエフエム デュー インコーポレイテッド | Compounds and compositions for treating conditions associated with STING activity |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| GB201908424D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
| US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| US10590087B1 (en) | 2019-08-09 | 2020-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
| EP4229037A2 (en) * | 2020-10-16 | 2023-08-23 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
| CN112250636A (en) * | 2020-11-09 | 2021-01-22 | 广西科技大学 | 5-aminoimidazole compound and synthesis method thereof |
| JP2024519215A (en) | 2021-05-07 | 2024-05-09 | カイメラ セラピューティクス， インコーポレイテッド | CDK2 degraders and their uses |
| EP4396159A1 (en) | 2021-09-01 | 2024-07-10 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| ZA987383B (en) * | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| ZA987385B (en) * | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| JP4533534B2 (en) * | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Inhibitor of glycogen synthase kinase 3 |
| WO2000021550A2 (en) * | 1998-10-13 | 2000-04-20 | President And Fellows Of Harvard College | Methods and compositions for treating neurodegenerative diseases |
| CO5160260A1 (en) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | SECRETAGOGOS OF THE HORMONE OF GROWTH DERIVED FROM IMI- DAZOL 1,4- SUBSTITUTED |
| DE69912808T2 (en) * | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Use of hymenialdisine and its derivatives for the preparation of therapeutic agents |
-
2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/en unknown
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/en not_active Expired - Fee Related
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/en not_active Ceased
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 EA EA200300097A patent/EA200300097A1/en unknown
- 2001-07-25 PL PL01365134A patent/PL365134A1/en not_active Application Discontinuation
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Ceased
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/en not_active Application Discontinuation
- 2001-07-25 CN CN01813397A patent/CN1444567A/en active Pending
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/en active IP Right Grant
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/en not_active Application Discontinuation
- 2001-07-25 IL IL15378701A patent/IL153787A0/en unknown
- 2001-07-25 EE EEP200300049A patent/EE200300049A/en unknown
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/en unknown
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/en unknown
- 2001-07-25 HR HR20030048A patent/HRP20030048A2/en not_active Application Discontinuation
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/en not_active IP Right Cessation
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/en not_active Application Discontinuation
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/en unknown
- 2001-07-30 AR ARP010103637A patent/AR032629A1/en unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/en not_active Application Discontinuation
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/en unknown
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/en unknown
-
2002
- 2002-12-18 CR CR6861A patent/CR6861A/en not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/en unknown
-
2003
- 2003-01-16 BG BG107469A patent/BG107469A/en unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/en unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/en unknown
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/en not_active Application Discontinuation
-
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2002000571A (en) | IMIDAZOL DERIVATIVES REF. PC10825 / 20211 / BB | |
| PA8528101A1 (en) | PIRAZOL DERIVATIVES | |
| BR0201691A (en) | Thiazole Derivatives | |
| SE0402735D0 (en) | Novel compounds | |
| BRPI0616574A2 (en) | sulfonamide derivative having pgd2 receptor antagonistic activity | |
| BRPI0418026A (en) | phenylalanine derivatives or pharmaceutically acceptable salts thereof, pharmaceutical composition, alpha4 integrin antagonist, and therapeutic or preventative agent for diseases | |
| NO20074620L (en) | Spiro heterocyclic compounds and their use as drugs | |
| BRPI0607926A2 (en) | spiro-oxindole compounds and their uses as therapeutic agents | |
| EP1609798A4 (en) | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | |
| NO20081844L (en) | Therapeutic compounds | |
| CY1110332T1 (en) | Benzimidazole derivatives, the compositions containing them, their preparation and their use | |
| ATE450533T1 (en) | CARBOXAMIDE DERIVATIVES | |
| DK1689721T3 (en) | Aminopyrazole derivatives as GSK-3 inhibitors | |
| UY28922A1 (en) | RECEIVER CB1 LINKS USEFUL IN THE TREATMENT OF PAIN AND / OR OTHER SYMPTOMS OR RELATED DISEASES; PHARMACEUTICAL COMPOUNDS AND THEIR PREPARATION. | |
| AR020032A1 (en) | DERIVATIVES OF 1,3-METHYL Erythromycin. | |
| BRPI0715698B8 (en) | product, pharmaceutical composition containing it and use of compound | |
| GT200900007A (en) | PURINE DERIVATIVES AS A2A AGONISTS | |
| BRPI0618380A2 (en) | pharmaceutical combination and its use | |
| AR044712A1 (en) | DERIVATIVES OF INDOL, PROCEDURES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF MEDICINES. | |
| BRPI0518785A2 (en) | 7-membered ring compound and method of production and pharmaceutical application thereof | |
| CL2004000779A1 (en) | COMPOUNDS DERIVED FROM 3-AZABICICLO [3.2.1] OCTANO, PHARMACEUTICAL COMPOSITION, PREPARATION PROCEDURE, USEFUL TO PREPARE MEDICATIONS TO TREAT IRRITABLE INTESTINE SYNDROME, RELEASE, NAUSEAS, VOMITES, SEXUAL DYSFUNCTION, ALZHE | |
| UY29394A1 (en) | SUBSTITUTED DERIVATIVES OF N- (5- (2-PROPILAMINE.1.HYDROXYETHYL) -2-HDROXIFENIL) METHANE SULFONAMIDE, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND APPLICATIONS. | |
| EE05300B1 (en) | A pharmaceutical composition comprising an acrylamine derivative, the use of a derivative for the preparation of an anti-tumor drug, and a combined pharmaceutical formulation. | |
| ECSP088968A (en) | MUSCARINIC RECEIVER AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | |
| Mishra et al. | Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse |